Piper Jaffray Companies restated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Monday, March 12th. The firm currently has a $76.12 price objective on the biotechnology company’s stock, down from their previous price objective of $83.00.
Several other analysts have also weighed in on SRPT. SunTrust Banks upped their target price on Sarepta Therapeutics to $76.00 and gave the company a buy rating in a report on Thursday, March 8th. Morgan Stanley upped their target price on Sarepta Therapeutics from $63.00 to $64.00 and gave the company an overweight rating in a report on Tuesday, March 6th. Credit Suisse Group set a $81.00 target price on Sarepta Therapeutics and gave the company a buy rating in a report on Friday, March 2nd. Nomura upped their target price on Sarepta Therapeutics to $96.00 and gave the company a buy rating in a report on Friday, March 2nd. Finally, HC Wainwright set a $75.00 target price on Sarepta Therapeutics and gave the company a buy rating in a report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $76.40.
SRPT stock traded down $1.11 during trading on Monday, hitting $78.80. The stock had a trading volume of 207,930 shares, compared to its average volume of 1,637,235. Sarepta Therapeutics has a twelve month low of $28.14 and a twelve month high of $84.37. The stock has a market capitalization of $5,232.06, a PE ratio of -98.50 and a beta of 1.52. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96.
Several large investors have recently modified their holdings of SRPT. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 977 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares in the last quarter. Prentiss Smith & Co. Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at $199,000. Brighton Jones LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at $211,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the fourth quarter worth about $217,000. Institutional investors and hedge funds own 84.93% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.